Drug Profile
LGD 3437
Alternative Names: LGD-3437Latest Information Update: 28 Oct 2019
Price :
$50
*
At a glance
- Originator Ligand Pharmaceuticals
- Class
- Mechanism of Action Histamine H3 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes - Hypersomnia
Highest Development Phases
- No development reported Hypersomnia
Most Recent Events
- 28 Oct 2019 No recent reports of development identified for preclinical development in Hypersomnia in USA
- 01 Sep 2015 LGD 3437 is available for licensing as of 01 Sep 2015. http://www.ligand.com/
- 01 Sep 2015 Preclinical trials in Hypersomnia in USA (unspecified route)